50 likes | 252 Views
Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD. Aim
E N D
Proposed comprehensive ototoxicity monitoring program for VAhealthcare (COMP-VA) Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD
Aim • Describe COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. • Relevance • With improved survivability following cancer treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.
Method • COMP-VA is designed to be administered on chemo-therapy treatment unit just before treatment (chairside). • Uses portable ototoxicity identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.
Clinical Objectives • Pretreatment ototoxicity risk assessment. • Behavioral screening for early hearing changes. • Screening for outer hair cell dysfunction. • Nonbehavioral screening for early hearing changes. • Screen failure follow-up testing. • Screening for tinnitus. • Patient and provider education about ototoxic-induced hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.
Conclusion • Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the-minute estimates of ototoxicity before patient’s next treatment. • This allows for timely consideration of treatment changes. • Program encourages efficient communication and team relationships between audiology and oncology.